OncoMatch/Clinical Trials/NCT06648434
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Is NCT06648434 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Zunsemetinib and mFOLFIRINOX for metastatic pancreatic ductal adenocarcinoma.
Treatment: Zunsemetinib · mFOLFIRINOX — The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Diagnosis of advanced inoperable or metastatic disease, where mFOLFIRINOX (or classical FOLFIRINOX) is deemed a suitable option per the treating physician. Measurable disease by RECIST 1.1.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: Prior adjuvant/neoadjuvant therapy (including FOLFIRINOX or mFOLFIRINOX regimens) is allowed if progression occurred ≥ 12 months from the last dose of that therapy.
no prior systemic treatment for advanced or metastatic disease. Prior adjuvant/neoadjuvant therapy (including FOLFIRINOX or mFOLFIRINOX regimens) is allowed if progression occurred ≥ 12 months from the last dose of that therapy.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 K/cumm; Platelets ≥ 100 K/cumm without transfusion within 2 weeks prior to C1D1; Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks prior to C1D1
Kidney function
Creatinine clearance > 50 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN, unless there are liver metastases in which case AST and ALT ≤ 5.0 x IULN
Cardiac function
Baseline EKG with QTcF ≤ 460 ms
Adequate bone marrow and organ function as defined below: Absolute neutrophil count ≥ 1.5 K/cumm; Platelets ≥ 100 K/cumm without transfusion within 2 weeks prior to C1D1; Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks prior to C1D1; Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN, unless there are liver metastases in which case AST and ALT ≤ 5.0 x IULN; Creatinine clearance > 50 mL/min by Cockcroft-Gault; Baseline EKG with QTcF ≤ 460 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify